home / stock / urgn / urgn short
Short Information | UroGen Pharma Ltd. (NASDAQ:URGN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,040,514 |
Total Actual Volume | 6,004,164 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 52,026 |
Average Short Percentage | 16.40% |
Is there a URGN Short Squeeze or Breakout about to happen?
See the URGN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-26-2024 | $13.97 | $14.15 | $14.32 | $13.69 | 135,569 | 27,849 | 20.54% |
04-25-2024 | $14.05 | $13.82 | $14.5 | $13.77 | 185,411 | 31,157 | 16.8% |
04-24-2024 | $14.66 | $14.21 | $14.758 | $14.19 | 97,025 | 14,366 | 14.81% |
04-23-2024 | $14.4 | $14.53 | $14.85 | $14.11 | 216,754 | 39,484 | 18.22% |
04-22-2024 | $13.8 | $14.37 | $14.52 | $13.58 | 278,571 | 41,860 | 15.03% |
04-19-2024 | $14.06 | $13.73 | $14.28 | $13.17 | 389,484 | 56,442 | 14.49% |
04-18-2024 | $14.36 | $14.26 | $14.54 | $13.96 | 315,348 | 83,525 | 26.49% |
04-17-2024 | $14.61 | $14.24 | $14.66 | $14.02 | 187,493 | 26,546 | 14.16% |
04-16-2024 | $14.86 | $14.49 | $15.05 | $14.15 | 409,956 | 50,346 | 12.28% |
04-15-2024 | $15.32 | $15.1 | $15.5 | $14.21 | 661,676 | 116,334 | 17.58% |
04-12-2024 | $13.09 | $15.1 | $15.21 | $13 | 1,228,983 | 264,526 | 21.52% |
04-11-2024 | $13.14 | $13.25 | $13.25 | $12.37 | 258,705 | 48,184 | 18.63% |
04-10-2024 | $13.2 | $12.95 | $13.2 | $12.58 | 378,477 | 52,189 | 13.79% |
04-09-2024 | $13.32 | $13.37 | $13.91 | $13.21 | 204,206 | 18,419 | 9.02% |
04-08-2024 | $13.64 | $13.21 | $13.64 | $13.18 | 125,207 | 18,580 | 14.84% |
04-05-2024 | $13.54 | $13.6 | $13.98 | $13.214 | 128,770 | 19,096 | 14.83% |
04-04-2024 | $13.77 | $13.64 | $14.3 | $13.5 | 236,482 | 44,601 | 18.86% |
04-03-2024 | $14 | $13.66 | $14.26 | $13.47 | 176,361 | 26,636 | 15.1% |
04-02-2024 | $14.28 | $14.09 | $14.515 | $13 | 194,218 | 30,885 | 15.9% |
04-01-2024 | $14.75 | $14.2 | $14.75 | $14.16 | 195,468 | 29,489 | 15.09% |
News, Short Squeeze, Breakout and More Instantly...
UroGen Pharma Ltd. Company Name:
URGN Stock Symbol:
NASDAQ Market:
Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term real-world analyses of JELMYTO® (mitomycin) for pyelocalyceal solution exploring its use in broad pa...
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process, simplify the reconstitution procedure, and potentially extend intellectu...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Tev...